BiotechTube

AGS-16C3F

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoma, Renal Cell

Conditions

Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology

Trial Timeline

Jul 18, 2012 → Feb 21, 2017

NCT ID
NCT01672775

About AGS-16C3F

AGS-16C3F is a phase 1 stage product being developed by Astellas Pharma for Carcinoma, Renal Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT01672775. Target conditions include Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01672775Phase 1Completed

Competing Products

20 competing products in Carcinoma, Renal Cell

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
33
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + CarboplatinEli LillyPhase 3
77
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
28
Cemiplimab + CetuximabEli LillyPhase 2
52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
25
BB-401Benitec BiopharmaPhase 2
44
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
AzenosertibZentalis PharmaceuticalsPhase 2
44
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
25
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
Ramucirumab + PaclitaxelEli LillyPhase 2
52
LY2875358 + ErlotinibEli LillyPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85